Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - AMERICAN BIO MEDICA CORP | abmc_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A-1
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): September 15,
2020
AMERICAN BIO MEDICA
CORPORATION
(Exact
name of registrant as specified in its charter)
New
York
|
0-28666
|
14-1702188
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification Number)
|
122 Smith Road,
Kinderhook, NY 12106
(Address of
principal executive offices) (Zip
Code)
Registrant’s
telephone number, including area code: 518-758-8158
Not applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2.
below):
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each
class
|
Trading
Symbol(s)
|
Name of each
exchange on which registered
|
Common
|
ABMC
|
Over-the-counter-Pink
Sheets
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
ITEM 2.02 RESULTS
OF OPERATIONS AND FINANCIAL CONDITION
On
September 15, 2020 American Bio Medica Corporation (the "Company")
announced financial results for the quarter ended June 30, 2020. A
copy of the press release announcing the Company’s results
(the "Press Release") is attached hereto as Exhibit 99.1 and is
incorporated by reference in this Item 2.02. The Press Release is
available on the Company’s website. The information provided
in Item 2.02 of this report, including Exhibit 99.1, shall be
deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended.
The
Company expects to file its Form 10-Q on September 15,
2020.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AMERICAN BIO MEDICA
CORPORATION (Registrant)
|
|
|
September 15,
2020 |
|
|
|
By:
|
/s/ Melissa A.
Waterhouse
|
|
|
|
|
Melissa A. Waterhouse |
|
|
|
Chief Executive
Officer (Principal Executive Officer)
Principal Financial
Officer
|
|